Acción INDSWFTLAB IND-SWIFT LABORATORIES LIMITED
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Ind-Swift Laboratories Limited Bombay S.E.

Acciones

INDSWFTLAB

INE915B01019

Mercado cerrado - Bombay S.E.
Otros sitios de cotización
 12:00:50 03/05/2024 		Varia. Cinco días. Varia. 1 de enero.
115,9 INR -6,00 % Gráfico intradía de Ind-Swift Laboratories Limited -7,11 % +11,52 %
19/04 Ind-Swift Laboratories Limited anuncia la incorporación de una filial de propiedad absoluta CI
18/03 Ind-Swift Laboratories Limited anuncia el cese de Sunil Deshmukh como Consejero Delegado CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Ind-Swift Laboratories to Incorporate Wholly-Owned Arm in Dubai
Ind-Swift Laboratories Limited Announces Incorporation of Wholly Owned Subsidiary
Ind-Swift Laboratories Limited Announces Cessation of Sunil Deshmukh as Chief Executive Officer
Ind-Swift Laboratories Limited Announces Cessation of Lovekesh Mahajan as Chief Accounts Officer
Ind-Swift Laboratories Limited Redeems in Full, the 4245 Rated, Listed, Secured, 10% Coupon, Redeemable, Non-Convertible Debenture
Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited and Essix Biosciences Limited.
Ind-Swift Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CARE Keeps BB Rating on Ind-Swift Laboratories' Long-term Financing; Rating Under Watch Developing
Ind-Swift Laboratories Limited Collaborates with The Council of Scientific and Industrial Research
Ind-Swift Laboratories Limited Reports Earnings Results for the Half Year Ended September 30, 2023
Ind-Swift Laboratories Limited agreed to acquire Ind-Swift Limited.
IndiaRF to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 1,650 Crores
Ind-Swift Gets Board Nod to Secure INR6 Billion Loan from Ind-Swift Laboratories
India's Ind-Swift Labs to sell pharma ingredients ops for $198.5 million
Synthimed Labs Private Limited agreed to acquire API and CRAMS business of Ind-Swift Laboratories Limited for INR 16.5 billion.
Ind-Swift Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
Ind-Swift Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023
RN Chemicals & Pharmaceutical Private Limited acquired Halcyon life Sciences Private Limited from Ind-Swift Laboratories Limited for INR 5 million.
Ind-Swift Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción INDSWFTLAB
  4. Acción INDSWFTLAB
  5. Noticias Ind-Swift Laboratories Limited
  6. Otros idiomas